Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
Stopped early · Phase 1
Conditions studied: Breast Cancer
In brief
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to receive their first dose of pembrolizumab before HIFU.
Key facts
- Study ID
- NCT03237572
- Run by
- Patrick Dillon, MD
- People needed
- 13
- Starts
- 2017-09-25
- Expected to finish
- 2022-06-17
- Last updated by the study team
- 2026-02-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Virginia — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.